

FOI 3464

15th December 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	21
1.2 Apalutamide (Erleada)	7
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	7
1.4 Darolutamide (Nubeqa)	36
1.5 Enzalutamide (Xtandi)	135
1.6 Talazoparib (Talzenna)	0
1.7 Docetaxel	0
1.8 Relugolix (Orgovyx, Ryego)	0
1.9 Olaparib (Lynparza)	10

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	
2.2 Olaparib (Lynparza) for prostate cancer	
2.3 Talazoparib (Talzenna) for prostate cancer	
2.4 Relugolix (Orgovyx) for prostate cancer	

Response: This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the

“appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	
3.2 Apalutamide (Erleada)	
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	
3.4 Darolutamide (Nubeqa)	
3.5 Enzalutamide (Xtandi)	

Response: Please see response to question 2.

Q4. How many patients were treated with the following combinations in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1</u> or <u>dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel		
4.2 Darolutamide (Nubeqa)		
4.3 Olaparib (Lynparza) + Abiraterone		

Response: Please see response to question 2.

Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Abiraterone	
5.2 Enzalutamide	

Response: Please see response to question 2.

Q6a. How many patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal cancer were treated with platinum chemotherapy between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

Q6b. How many patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal cancer received maintenance therapy between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

Q6c. How many patients were treated with olaparib (Lynparza) for the following types of cancer between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

Type of cancer	ICD-10 codes	Number of patients
a. Breast Cancer	C50* or D05	
b. Ovarian Cancer	C56* or C57* or C79.6 or C79.8 or C48.1 or C48.2	
c. Prostate Cancer	C61*	

Response: Please see response to question 2.

Q6d. How many patients were treated with olaparib (Lynparza) for the following indications and BlueTeq CDF codes between 1st Jul 2025 and 30th Sep 2025, or latest 3-month period for which data is available?

BlueTeq CDF code	BlueTeq CDF description (copied from CDF List)	Number of patients
OLAP1a or OLAPb	Maintenance treatment in patients with high grade epithelial stage III or IV <u>ovarian, fallopian tube or primary peritoneal carcinoma</u> who are in <u>response following platinum-based FIRST line chemotherapy</u> AND have a deleterious or suspected deleterious germline and/or somatic BRCA mutation	
OLAP 2	Maintenance treatment in patients with high grade epithelial <u>ovarian, fallopian tube or primary peritoneal carcinoma</u> who HAVE a deleterious or suspected deleterious germline and/or somatic BRCA mutation and a recent FIRST RELAPSE of platinum- sensitive disease and are now <u>in response following a SECOND platinum- based chemotherapy</u>	
OLAP 3	Maintenance treatment in patients with high grade epithelial <u>ovarian, fallopian tube or primary peritoneal carcinoma</u> who have a deleterious or suspected deleterious germline and/or somatic BRCA mutation and a recent SECOND OR SUBSEQUENT relapse of platinum-sensitive disease and are now <u>in response following a THIRD OR SUBSEQUENT platinum-based chemotherapy</u>	
OLAP 4	Maintenance treatment in patients with high grade epithelial stage III or IV <u>ovarian, fallopian tube or primary peritoneal carcinoma</u> who are in response following platinum-based FIRST line chemotherapy AND whose cancer has a positive status for homologous recombination deficiency as defined by the presence of either a deleterious or suspected deleterious BRCA 1/2 germline and/or somatic mutation or genomic instability	
OLAP 5	Olaparib monotherapy as <u>adjuvant</u> treatment of high-risk <u>TRIPLE NEGATIVE early breast cancer</u> treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation	
OLAP 6	<u>Adjuvant</u> treatment of high-risk <u>HORMONE RECEPTOR POSITIVE HER 2 NEGATIVE early breast cancer</u> treated with neoadjuvant or adjuvant chemotherapy and definitive local	

	therapy in patients with a deleterious or suspected deleterious germline BRCA mutation	
OLAP 7	Olaparib monotherapy for <u>metastatic castration-resistant prostate cancer</u> bearing germline and/or somatic <u>BRCA 1 or 2 mutations</u> in patients who have progressed following previous treatment with an androgen receptor targeted agent AND HAVE ALSO BEEN TREATED WITH DOCETAXEL	
OLAP 8	Olaparib monotherapy for <u>metastatic castration-resistant prostate cancer</u> bearing germline and/or somatic <u>BRCA 1 or 2 mutations</u> in patients who have progressed following previous treatment with an androgen receptor targeted agent AND HAVE NOT BEEN PREVIOUSLY TREATED WITH DOCETAXEL	
OLAP 9	Olaparib + abiraterone for the treatment of <u>metastatic hormone- relapsed (castrate-resistant) prostate cancer</u> in patients who are treatment naïve to androgen receptor inhibitors and in whom chemotherapy is not yet clinically indicated or appropriate	

Response: Please see response to question 2.

Email: Foi.Team@Southerntrust.hscni.net